Prof Johan Neyts | +32 16 33 7367

The focus of Prof J. Neyts is the development of novel antiviral strategies. His work has been published in more than 300 peer reviewed papers and in a number of bookchapters. He is the holder of several patents, discoveries include the HCV inhibitors Tegobuvir and Alisporivir and a class of potent dengue inhibitors (currently in development at Johnson & Johnson). He has been partner in 10 EU funded projects, iseditor of the journal Antiviral Research and on the board of directors of the International Society for Antiviral Research. He is the co-founder of the spin-out company Okapi Sciences NV (now acquired by Aratana Therapeutics) which is developing antivirals for use in veterinary medicine. He teaches medical virology at the school of dentistry and the school of medicine at the University of Leuven. He has been honored with a number of awards including from the International Society for Antiviral Research, the Royal Belgian Academy of Medicine and the Belgian Fund for Scientific Research. Website Neyts laboratory 

Relevant Publications

Thibaut HJ, van der Linden L, Jiang P, Thys B, Canela MD, Aguado L, Rombaut B, Wimmer E, Paul A, Pérez-Pérez MJ, van Kuppeveld F, Neyts J. Binding of glutathione to enterovirus capsids is essential for virion morphogenesis. PLoS Pathogens; (2014) 10(4):e1004039

Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 50: 6-16 (2009)

Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J. The non-immuno-suppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43: 761-770, (2006)

Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG, van der Zeijst BA, Osterhaus AD. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439: 745-748 (2006)

Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol. (2005) J Virol. 79:1943-7